| 1 |
34331013 | Synergistic melanoma cell death mediated by inhibition of both MCL1 and BCL2 in high-risk tumors driven by NF1/PTEN loss. | 2021 Sep |
1 |
| 2 |
32062191 | Rapamycin inhibits B-cell activating factor (BAFF)-stimulated cell proliferation and survival by suppressing Ca2+-CaMKII-dependent PTEN/Akt-Erk1/2 signaling pathway in normal and neoplastic B-lymphoid cells. | 2020 May |
1 |
| 3 |
28186963 | An oral quinoline derivative, MPT0B392, causes leukemic cells mitotic arrest and overcomes drug resistant cancer cells. | 2017 Apr 25 |
1 |
| 4 |
25780003 | Expression of Bcl-xL and Mcl-1 in the nonmelanoma skin cancers of renal transplant recipients. | 2015 Apr |
2 |
| 5 |
26452980 | Co-administration of the mTORC1/TORC2 inhibitor INK128 and the Bcl-2/Bcl-xL antagonist ABT-737 kills human myeloid leukemia cells through Mcl-1 down-regulation and AKT inactivation. | 2015 Dec |
1 |
| 6 |
23741975 | Rapamycin interacts synergistically with idarubicin to induce T-leukemia cell apoptosis in vitro and in a mesenchymal stem cell simulated drug-resistant microenvironment via Akt/mammalian target of rapamycin and extracellular signal-related kinase signaling pathways. | 2014 Mar |
1 |
| 7 |
23580240 | Concurrent inhibition of PI3K and mTORC1/mTORC2 overcomes resistance to rapamycin induced apoptosis by down-regulation of Mcl-1 in mantle cell lymphoma. | 2013 Oct 15 |
2 |
| 8 |
22190165 | Sorafenib, a multikinase inhibitor, is effective in vitro against non-Hodgkin lymphoma and synergizes with the mTOR inhibitor rapamycin. | 2012 Mar |
1 |
| 9 |
21083937 | Rapamycin sensitizes T-ALL cells to dexamethasone-induced apoptosis. | 2010 Nov 18 |
1 |
| 10 |
17010674 | Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance. | 2006 Oct |
1 |